|
HB 317 (BR 1241) - M. Marzian, M. Dedman Jr., C. Hoffman, J. Jenkins
AN ACT relating to health care services provided in clinical trials for the treatment of cancer.
Create a new section of Subtitle 17A of KRS Chapter 304 to require a health benefit plan to cover health care services for the treatment of cancer in a clinical trial if those services would be covered if not provided in a clinical trial; require clinical trials to meet therapeutic criteria and be approved by appropriate agencies; provide that this coverage is not a health benefit mandate.
HB 317 - AMENDMENTS
HCS - Create a new section of Subtitle 17A of KRS Chapter 304 to prohibit a health benefit plan from excluding coverage for routine patient healthcare costs that are incurred in the course of a cancer clinical trial if the health benefit plan would provide coverage for the routine patient healthcare cost had it not been incurred in a cancer clinical trial; provide that nothing in this section requires a policy to offer, nor prohibits a policy from offering, cancer clinical trial services by a participating provider; provide that nothing in this section requires services that are performed in a cancer clinical trial by a nonparticipating provider of a policy to be reimbursed at the same rate as a participating provider of the policy.
HFA (1, M. Marzian) - Retain original provisions except delete language in definition of "cancer clinical trial" referencing "Phase III clinical trial"; insert language requiring that the cancer clinical trial be approved by the National Institutes of Health, or any institutional review board recognized by the National Institutes of Health, The United States Food and Drug Administration, The United States Department of Defense, or The United States Veterans Administration.
HFA (2, M. Marzian) - Retain original provisions except delete language in definition of "cancer clinical trial" referencing "Phase III clinical trial"; insert language requiring that the cancer clinical trial be approved by the National Institutes of Health, or any institutional review board recognized by the National Institutes of Health, The United States Food and Drug Administration, The United States Department of Defense, or The United States Veterans Administration, delete language defining "routine patient healthcare costs"; insert language redefining "routine patient healthcare costs" to mean all healthcare services, items, and drugs for the treatment of cancer.
Jan 16-introduced in House
Jan 17-to Banking & Insurance (H)
Jan 24-posted in committee
Feb 13-reported favorably, 1st reading, to Calendar with Committee Substitute
Feb 14-2nd reading, to Rules
Feb 15-floor amendments (1) and (2) filed to Committee Substitute
Feb 19-posted for passage in the Regular Orders of the Day for Wednesday, February 20, 2008
Mar 4-3rd reading, passed 97-0 with Committee Substitute, floor amendment (2)
Mar 5-received in Senate
Mar 7-to Banking & Insurance (S)
Mar 25-reported favorably, 1st reading, to Consent Calendar
Mar 26-2nd reading, to Rules
Vote History
|
